|
| Wednesday, December 13, 2017 |
|
|
エーザイ、「アリセプト(R)」が中国において高度アルツハイマー型認知症に関する適応追加の承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、「アリセプト(R)」（一般名：ドネペジル塩酸塩、中国語表記：安理申(R))について、中国において高度アルツハイマー型認知症に関する適応追加の承認を取得したことをお知らせします。本承認によって「アリセプト」は、中国において、軽度から高度までアルツハイマー型認知症に関する幅広い適応を有する初めての治療薬となりました。 more info >> |
|
| Friday, December 8, 2017 |
|
|
エーザイ、エリブリンとペムブロリズマブ併用による転移性トリプルネガティブ乳がんを対象とした臨床第Ib/II相試験のアップデート解析について発表 |
| エーザイ、エリブリンとペムブロリズマブ併用による転移性トリプルネガティブ乳がんを対象とした臨床第Ib/II相試験のアップデート解析についてサンアントニオ乳がんシンポジウムにて発表 more info >> |
|
|
Eisai: Updated Analysis of Phase Ib/II Study of Eribulin and Pembrolizumab Combination Regimen |
| Eisai Co., Ltd. announced today that a presentation on the updated analysis of a global Phase Ib/II clinical study of its in-house discovered and developed anticancer agent eribulin mesylate in combination with the anti-PD-1 therapy pembrolizumab developed by Merck & Co., Inc. more info >> |
|
| Wednesday, December 6, 2017 |
|
|
Eisai Submits Application for Expanded Indication Covering Hepatocellular Carcinoma for Anticancer Agent Lenvima in Taiwan |
| Eisai Co., Ltd. announced that it has submitted an application for its in-house discovered and developed anticancer agent lenvatinib mesylate (product names: Lenvima/Kisplyx, product name in Taiwan: "Lenvima") for an additional indication for use in the treatment of hepatocellular carcinoma (HCC) in Taiwan. more info >> |
|
|
エーザイ、抗がん剤「レンビマ(R)」が台湾において肝細胞がんに係る適応拡大を申請 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、自社創製の抗がん剤レンバチニブメシル酸塩（一般名、製品名：「レンビマ(R)」 「Kisplyx(R)」 、台湾製品名：「樂衛瑪(R)」、以下「レンビマ」）について、台湾において肝細胞がんに係る適応で効能・効果追加の申請を行ったことをお知らせします。今回の「レンビマ」の肝細胞がんに係る適応の申請は、アジアにおいて日本・中国に続く申請となります。 more info >> |
|
| Thursday, November 30, 2017 |
|
|
Eisai's Resubmitted NDA for Anticancer Agent Halaven Accepted in China |
| Eisai Co., Ltd. announced today that the China Food and Drug Administration (CFDA) has accepted for review the resubmitted New Drug Application (NDA) for Eisai's anticancer agent eribulin mesylate (eribulin, product name: Halaven). more info >> |
|
| Wednesday, November 29, 2017 |
|
|
エーザイ、中国における抗がん剤「ハラヴェン(R)」の新薬承認の再申請が受理 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、本日、抗がん剤エリブリンメシル酸塩（製品名：「ハラヴェン(R)」）について、中国における新薬承認申請を再提出し、国家食品薬品監督管理総局に受理されたことをお知らせします。 more info >> |
|
| Friday, November 24, 2017 |
|
|
Eisai to Present Latest Data on Perampanel and Rufinamide at 71st American Epilepsy Society Annual Meeting |
| Eisai Co., Ltd. announced today that the latest data on its antiepileptic drugs (AED) perampanel and rufinamide will be presented at the 71st American Epilepsy Society (AES) Annual Meeting to be held from December 1 to 5, 2017 in Washington D.C. in the United States. more info >> |
|
| Thursday, February 20, 2025 |
|
|
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives |
| Eisai Co., Ltd. announced today that it has been selected for "Human CapitalLeaders 2024" and "Human Capital Management Gold Quality" in the "Human Capital Survey 2024" jointly conducted by HR Technology Consortium, HR Research Institute (ProFuture Inc.), MS&AD InterRisk Research & Consulting, Inc. and Association to Confirm the Human Investment Value for Enterprise. more info >> |
|
| Friday, February 14, 2025 |
|
|
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease |
| Oita University and Eisai Co., Ltd. announced today the development of a machine learning model to predict amyloid beta (Abeta) accumulation in the brain, combining background data such as age, gender, smoking history and medical history, as well as general blood test and MMSE items. more info >> |
|
|
|
|
